nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/NanoSmart-Receives-Patent-Allowance-for-Tumor-Targ.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals. 2013 NanoSmart Pharmaceuticals, Inc. Pharmaceuticals,...
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/NanoSmart®-Opens-New-Headquaters-and-Begins-Develo.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals. 2013 NanoSmart Pharmaceuticals, Inc. Pharmaceuticals,...
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/Dr-James-Smith-provides-insight-on-the-current-ven.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals.
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/Tumor-Targeting-Platform-Delivers-the-Next-Generat.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals.
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/Dr-James-Smith.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals. 2013 NanoSmart Pharmaceuticals, Inc.
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/NanoSmart-Joins-Forces-with-Childrens-Hospital.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals. 2013 NanoSmart Pharmaceuticals, Inc. Pharmaceuticals,...
nanosmartpharma.com
NanoSmart® Pharmaceuticals, Inc. - Nanosmart Pharmaceuticals, Inc
http://www.nanosmartpharma.com/Newsroom/NanoSmart®-Pharmaceuticals-and-UCLA-Enter-Collabor.aspx
NanoSmart Welcomes Kay Metis as VP of Strategic Alliances. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer. NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewing’s Sarcoma. NanoValent and NanoSmart Enter Strategic Research Collaboration to Develop Enhanced Cancer Pharmaceuticals. LAGUNA HILLS, CA, January 16, 2013 – NanoSmart. Pharm...
SOCIAL ENGAGEMENT